High-Grade Endometrial Carcinomas

Surgical Pathology Clinics

Volumn 4, Issue 1, 2011, Pages 199-241

  Oliva, Esther ^a   Soslow, Robert A ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Clear cell carcinoma; FIGO grade 3 endometrioid carcinoma; High grade endometrial carcinoma; High grade endometrioid carcinoma; Malignant mixed m llerian tumor; Serous carcinoma; Undifferentiated carcinoma

Indexed keywords

CYTOKERATIN; ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 1BETA; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P16; PROTEIN P53;

CELL ULTRASTRUCTURE; CLEAR CELL CARCINOMA; CLINICAL FEATURE; CYTOPLASM; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; MIXED MULLERIAN TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; UNDIFFERENTIATED CARCINOMA;

EID: 79951794123     PISSN: 18759181     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.path.2010.12.008     Document Type: Review

References (164)

1. Soslow R.A., Bissonnette J.P., Wilton A., et al. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol 2007, 31(7):979-987.
2. Catasus L., Gallardo A., Cuatrecasas M., et al. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol 2009, 22(4):522-529.
3. Soslow R.A., Shen P.U., Chung M.H., et al. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma. Int J Gynecol Pathol 1998, 17:129-134.
4. Lax S.F., Kendall B., Tashiro H., et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma - evidence of distinct molecular genetic pathways. Cancer 2000, 88(4):814-824.
5. Alvarez T., Bhan A.K., Miller E., et al. Molecular profile of grade 3 endometrial endometrioid carcinoma: is it a type I or type II endometrial carcinoma?. Mod Pathol 2005, 18(Suppl 1):177A. [abstract 820].
6. Feng Y.Z., Shiozawa T., Horiuchi A., et al. Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas. Virchows Arch 2005, 447(5):816-822.
7. Halperin R., Zehavi S., Habler L., et al. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol 2001, 22(2):122-126.
8. Reid-Nicholson M., Iyengar P., Hummer A.J., et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 2006, 19(8):1091-1100.
9. Dupont J., Wang X., Marshall D.S., et al. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecol Oncol 2004, 94(2):449-455.
10. Carcangiu M.L., Radice P., Casalini P., et al. Lynch syndrome-related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types. Int J Surg Pathol 2010, 18(1):21-26.
11. Garg K., Leitao M.M., Kauff N.D., et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol 2009, 33(6):925-933.
12. Broaddus R.R., Lynch H.T., Chen L.M., et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 2006, 106(1):87-94.
13. Carcangiu M.L., Tan L.K., Chambers J.T. Stage IA uterine serous carcinoma. A study of 13 cases. Am J Surg Pathol 1997, 21(12):1507-1514.
14. McCluggage W.G., Sumathi V.P., McManus D.T. Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyps: report of 5 cases, including 2 associated with tamoxifen therapy. Hum Pathol 2003, 34(9):939-943.
15. Hui P., Kelly M., O'Malley D.M., et al. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Mod Pathol 2005, 18(1):75-82.
16. Wheeler D.T., Bell K.A., Kurman R.J., et al. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol 2000, 24(6):797-806.
17. Silva E.G., Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol 1990, 3(2):120-128.
18. Sherman M.E., Bitterman P., Rosenshein N.B., et al. Uterine serous carcinoma: a morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992, 16:600-610.
19. Ambros R.A., Sherman M.E., Zahn C.M., et al. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995, 26:1260-1267.
20. Goff B.A., Kato D., Schmidt R.A., et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994, 54:264-268. [see comments].
21. Hendrickson M., Martinez A., Ross J., et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982, 6:93-108.
22. Lee K.R., Belinson J.L. Recurrence in noninvasive endometrial carcinoma: relationship to uterine papillary serous carcinoma. Am J Surg Pathol 1991, 15:965-973.
23. Williams K.E., Waters E.D., Woolas R.P., et al. Mixed serous-endometrioid carcinoma of the uterus: pathologic and cytopathologic analysis of a high-risk endometrial carcinoma. Int J Gynecol Cancer 1994, 4:7-18.
24. Carcangiu M.L., Chambers J.T. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 1992, 47:298-305.
25. Posligua L., Malpica A., Liu J., et al. Combined large cell neuroendocrine carcinoma and papillary serous carcinoma of the endometrium with pagetoid spread. Arch Pathol Lab Med 2008, 132(11):1821-1824.
26. Jordan L.B., Abdul-Kader M., Al-Nafussi A. Uterine serous papillary carcinoma: histopathologic changes within the female genital tract. Int J Gynecol Cancer 2001, 11(4):283-289.
27. Horn L.C., Hanel C., Bartholdt E., et al. Mixed serous carcinoma of the endometrium with trophoblastic differentiation: analysis of the p53 tumor suppressor gene suggests stem cell origin. Ann Diagn Pathol 2008, 12(1):1-3.
28. Sherman M.E., Bur M.E., Kurman R.J. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995, 26:1268-1274.
29. Spiegel G.W. Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol 1995, 19:417-432.
30. Soslow R.A., Pirog E., Isacson C. Endometrial intraepithelial carcinoma with associated peritoneal carcinomatosis. Am J Surg Pathol 2000, 24(5):726-732.
31. Tashiro H., Isacson C., Levine R., et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997, 150(1):177-185.
32. Chiesa-Vottero A.G., Malpica A., Deavers M.T., et al. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol 2007, 26(3):328-333.
33. Trahan S., Tetu B., Raymond P.E. Serous papillary carcinoma of the endometrium arising from endometrial polyps: a clinical, histological, and immunohistochemical study of 13 cases. Hum Pathol 2005, 36(12):1316-1321.
34. Vang R., Barner R., Wheeler D.T., et al. Immunohistochemical staining for Ki-67 and p53 helps distinguish endometrial Arias-Stella reaction from high-grade carcinoma, including clear cell carcinoma. Int J Gynecol Pathol 2004, 23(3):223-233.
35. Egan J.A., Ionescu M.C., Eapen E., et al. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int J Gynecol Pathol 2004, 23(2):119-122.
36. Yemelyanova A., Ji H., Shih IeM., et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol 2009, 33(10):1504-1514.
37. Alkushi A., Clarke B.A., Akbari M., et al. Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol 2007, 20(11):1156-1165.
38. Nofech-Mozes S., Khalifa M.A., Ismiil N., et al. Immunophenotyping of serous carcinoma of the female genital tract. Mod Pathol 2008, 21(9):1147-1155.
39. Acs G., Pasha T., Zhang P.J. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 2004, 23(2):110-118.
40. Schmitz M.J., Hendricks D.T., Farley J., et al. p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma. Gynecol Oncol 2000, 77(3):439-445.
41. Holcomb K., Delatorre R., Pedemonte B., et al. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet Gynecol 2002, 100(6):1290-1295.
42. Cassia R., Moreno-Bueno G., Rodriguez-Perales S., et al. Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. J Pathol 2003, 201(4):589-595.
43. Silverberg S.G., De Giorgi L.S. Clear cell carcinoma of the endometrium. Clinical, pathologic, and ultrastructural findings. Cancer 1973, 31:1127-1140.
44. Silva E.G., Young R.H. Endometrioid neoplasms with clear cells: a report of 21 cases in which the alteration is not of typical secretory type. Am J Surg Pathol 2007, 31(8):1203-1208.
45. Clement P.B., Young R.H. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 2004, 11(3):117-142.
46. Lax S.F., Pizer E.S., Ronnett B.M., et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol 1998, 29(6):551-558.
47. Abeler V.M., Kjorstad K.E. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol Oncol 1991, 40:207-217.
48. Malpica A., Tornos C., Burke T.W., et al. Low-stage clear-cell carcinoma of the endometrium. Am J Surg Pathol 1995, 19:769-774.
49. Kanbour-Shakir A., Tobon H. Primary clear cell carcinoma of the endometrium: a clinicopathologic study of 20 cases. Int J Gynecol Pathol 1991, 10:67-78.
50. Abeler V.M., Vergote I.B., Kjorstad K.E., et al. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer 1996, 78(8):1740-1747.
51. Kurman R.J., Scully R.E. Clear cell carcinoma of the endometrium: an analysis of 21 cases. Cancer 1976, 37:872-882.
52. Prat J., Oliva E., Lerma E., et al. Uterine papillary serous adenocarcinoma: a 10-case study of p53 and c-erbB-2 expression and DNA content. Cancer 1994, 74:1778-1783.
53. Logani S., Soslow R.A., Oliva E., et al. Is pure uterine clear cell carcinoma clinically distinct from endometrioid/serous carcinoma with a clear cell component?. Mod Pathol 2005, 18(Suppl 1):193A. [abstract 896].
54. Fadare O., Liang S.X., Cagnur U.E., et al. Precursors of endometrial clear cell carcinoma. Am J Surg Pathol 2006, 30(12):1519-1530.
55. Vang R., Whitaker B.P., Farhood A.I., et al. Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract. Int J Gynecol Pathol 2001, 20(3):252-259.
56. Arai T., Watanabe J., Kawaguchi M., et al. Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma. Int J Gynecol Cancer 2006, 16(1):391-395.
57. An H.J., Logani S., Isacson C., et al. Molecular characterization of uterine clear cell carcinoma. Mod Pathol 2004, 17(5):530-537.
58. Coosemans A., Moerman P., Verbist G., et al. Wilms' tumor gene 1 (WT1) in endometrial carcinoma. Gynecol Oncol 2008, 111(3):502-508.
59. Rolitsky C.D., Theil K.S., McGaughy V.R., et al. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol 1999, 18(2):138-143.
60. Khalifa M.A., Mannel R.S., Haraway S.D., et al. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994, 53:84-92.
61. Yamamoto S., Tsuda H., Aida S., et al. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol 2007, 38(7):1074-1080.
62. Han G., DeLair D., Gilks C.B., et al. Endometrial adenocarcinoma with clear cell morphology: interovserver variability and immunohistochemical analysis using hepatocyte nuclear factor-1 β. Mod Pathol 2010, 23(Suppl 1):245A. [abstract 1097].
63. Kobel M., Kalloger S.E., Carrick J., et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009, 33(1):14-21.
64. Risinger J.I., Maxwell G.L., Chandramouli G.V., et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 2003, 63(1):6-11.
65. Maxwell G.L., Chandramouli G.V., Dainty L., et al. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. Clin Cancer Res 2005, 11(11):4056-4066.
66. Zorn K.K., Bonome T., Gangi L., et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005, 11(18):6422-6430.
67. Garg K., Shih K., Barakat R., et al. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am J Surg Pathol 2009, 33(12):1869-1877.
68. Altrabulsi B., Malpica A., Deavers M.T., et al. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol 2005, 29(10):1316-1321.
69. Tafe L.J., Garg K., Chew I., et al. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol 2010, 23(6):781-789.
70. Alkushi A., bdul-Rahman Z.H., Lim P., et al. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol 2005, 29(3):295-304.
71. Silverberg S.G., DeGiorgi L.S. Histopathologic analysis of preoperative radiation therapy in endometrial carcinoma. Am J Obstet Gynecol 1974, 119(5):698-704.
72. Kraus F.T. Irradiation changes in the uterus 1973, Williams & Wilkins, Baltimore (MD).
73. Hendrickson M.R., Kempson R.L. Endometrial epithelial metaplasias: proliferations frequently misdiagnosed as adenocarcinoma. Report of 89 cases and proposed classification. Am J Surg Pathol 1980, 4:525-542.
74. Shah S.S., Mazur M.T. Endometrial eosinophilic syncytial change related to breakdown: immunohistochemical evidence suggests a regressive process. Int J Gynecol Pathol 2008, 27(4):534-538.
75. Horree N., Heintz A.P., Sie-Go D.M., et al. p16 is consistently expressed in endometrial tubal metaplasia. Cell Oncol 2007, 29(1):37-45.
76. Shimizu K., Norimatsu Y., Kobayashi T.K., et al. Expression of immunoreactivity and genetic mutation in eosinophilic and ciliated metaplastic changes of endometrial glandular and stromal breakdown: cytodiagnostic implications. Ann Diagn Pathol 2009, 13(2):89-95.
77. Quddus M.R., Sung C.J., Zheng W., et al. p53 immunoreactivity in endometrial metaplasia with dysfunctional uterine bleeding. Histopathology 1999, 35(1):44-49.
78. Arias-Stella J. The Arias-Stella reaction: facts and fancies four decades after. Adv Anat Pathol 2002, 9(1):12-23.
79. Tornos C., Silva E.G., Ordonez N.G., et al. Endometrioid carcinoma of the ovary with a prominent spindle-cell component, a source of diagnostic confusion. A report of 14 cases. Am J Surg Pathol 1995, 19:1343-1353.
80. Murray S.K., Clement P.B., Young R.H. Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms. Am J Surg Pathol 2005, 29(2):157-166.
81. Goodman A., Zukerberg L.R., Rice L.W., et al. Squamous cell carcinoma of the endometrium: a report of eight cases and a review of the literature. Gynecol Oncol 1996, 61:54-60.
82. Zidi Y.S., Bouraoui S., Atallah K., et al. Primary in situ squamous cell carcinoma of the endometrium, with extensive squamous metaplasia and dysplasia. Gynecol Oncol 2003, 88(3):444-446.
83. Rodolakis A., Papaspyrou I., Sotiropoulou M., et al. Primary squamous cell carcinoma of the endometrium. A report of 3 cases. Eur J Gynaecol Oncol 2001, 22(2):143-146.
84. Kondis A., Liapis A., Kairi E., et al. Primary squamous cell carcinoma of the endometrium. Immunopathological study of a case. Eur J Gynaecol Oncol 1999, 20(3):235-236.
85. Kataoka A., Nishida T., Sugiyama T., et al. Squamous cell carcinoma of the endometrium with human papillomavirus type 31 and without tumor suppressor gene p53 mutation. Gynecol Oncol 1997, 65:180-184.
86. Im D.D., Shah K.V., Rosenshein N.B. Report of three new cases of squamous carcinoma of the endometrium with emphasis in the HPV status. Gynecol Oncol 1995, 56:464-469.
87. Chew I., Post M.D., Carinelli S.G., et al. p16 expression in squamous and trophoblastic lesions of the upper female genital tract. Int J Gynecol Pathol 2010, 29(6):513-522.
88. Horn L.C., Richter C.E., Einenkel J., et al. p16, p14, p53, cyclin D1, and steroid hormone receptor expression and human papillomaviruses analysis in primary squamous cell carcinoma of the endometrium. Ann Diagn Pathol 2006, 10(4):193-196.
89. Giordano G., Azzoni C., D'Adda T., et al. P16(INK4a) overexpression independent of Human Papilloma Virus (HPV) infection in rare subtypes of endometrial carcinomas. Pathol Res Pract 2007, 203(7):533-538.
90. Spiegel G.W., Austin R.M., Gelven P.L. Transitional cell carcinoma of the endometrium. Gynecol Oncol 1996, 60:325-330.
91. Lininger R.A., Ashfaq R., Albores-Saavedra J., et al. Transitional cell carcinoma of the endometrium and endometrial carcinoma with transitional cell differentiation. Cancer 1997, 79(10):1933-1943.
92. Marino-Enriquez A., Gonzalez-Rocha T., Burgos E., et al. Transitional cell carcinoma of the endometrium and endometrial carcinoma with transitional cell differentiation: a clinicopathologic study of 5 cases and review of the literature. Hum Pathol 2008, 39(11):1606-1613.
93. Park K.J., Lamb C., Oliva E., et al. Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus. Mod Pathol 2008, 21(Suppl 1):217A. [abstract 993].
94. Albores-Saavedra J., Martinez-Benitez B., Luevano E. Small cell carcinomas and large cell neuroendocrine carcinomas of the endometrium and cervix: polypoid tumors and those arising in polyps may have a favorable prognosis. Int J Gynecol Pathol 2008, 27(3):333-339.
95. Mulvany N.J., Allen D.G. Combined large cell neuroendocrine and endometrioid carcinoma of the endometrium. Int J Gynecol Pathol 2008, 27(1):49-57.
96. Odunsi K., Olatinwo M., Collins Y., et al. Primary primitive neuroectodermal tumor of the uterus: a report of two cases and review of the literature. Gynecol Oncol 2004, 92(2):689-696.
97. Daya D., Lukka H., Clement P.B. Primitive neuroectodermal tumors of the uterus: a report of four cases. Hum Pathol 1992, 23:1120-1129.
98. Alkushi A., Kobel M., Kalloger S.E., et al. High grade endometrial carcinoma: Serous and grade 3 endometrioid carcinoma have different immunophenotypes and outcomes. Mod Pathol 2009, 22(Suppl 1):206A. [abstract 934].
99. Oliva E., Young R.H., Amin M.B., et al. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus. A study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol 2002, 26(4):403-412.
100. Kurman R.J., Norris H.J. Mesenchymal tumors of the uterus. VI. Epithelioid smooth muscle tumors including leiomyoblastoma and clear cell leiomyoma: a clinical and pathological analysis of 26 cases. Cancer 1976, 37:1853-1865.
101. Prayson R.A., Goldblum J.R., Hart W.R. Epithelioid smooth-muscle tumors of the uterus. A clinicopathologic study of 18 patients. Am J Surg Pathol 1997, 21(4):383-391.
102. Silva E.G., Tornos C., Ordóñez N.G., et al. Uterine leiomyosarcoma with clear cell areas. Int J Gynecol Pathol 1995, 14:174-178.
103. Iwata J., Fletcher C.D. Immunohistochemical detection of cytokeratin and epithelial membrane antigen in leiomyosarcoma: a systematic study of 100 cases. Pathol Int 2000, 50(1):7-14.
104. O'Neill C.J., McCluggage W.G. p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol 2006, 13(1):8-15.
105. Vang R., Kempson R.L. Perivascular epithelioid cell tumor ('PEComa') of the uterus: a subset of HMB-45-positive epithelioid mesenchymal neoplasms with an uncertain relationship to pure smooth muscle tumors. Am J Surg Pathol 2002, 26(1):1-13.
106. Folpe A.L., Mentzel T., Lehr H.A., et al. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol 2005, 29(12):1558-1575.
107. Lifschitz-Mercer B., Czernobilsky B., Dgani R., et al. Immunocytochemical study of an endometrial diffuse clear cell stromal sarcoma and other endometrial stromal sarcomas. Cancer 1987, 59:1494-1499.
108. Baergen R.N., Rutgers J.L., Young R.H., et al. Placental site trophoblastic tumor: a study of 55 cases and review of the literature emphasizing factors of prognostic significance. Gynecol Oncol 2006, 100(3):511-520.
109. Shih I.M., Kurman R.J. Immunohistochemical localization of inhibin-alpha in the placenta and gestational trophoblastic lesions. Int J Gynecol Pathol 1999, 18(2):144-150.
110. Pelkey T.J., Frierson H.F., Mills S.E., et al. Detection of the alpha-subunit of inhibin in trophoblastic neoplasia. Hum Pathol 1999, 30(1):26-31.
111. Shih I.M., Seidman J.D., Kurman R.J. Placental site nodule and characterization of distinctive types of intermediate trophoblast. Hum Pathol 1999, 30(6):687-694.
112. Nielsen G.P., Oliva E., Young R.H., et al. Alveolar soft-part sarcoma of the female genital tract: a report of nine cases and review of the literature. Int J Gynecol Pathol 1995, 14:283-292.
113. Roma A.A., Yang B., Senior M.E., et al. TFE3 immunoreactivity in alveolar soft part sarcoma of the uterine cervix: case report. Int J Gynecol Pathol 2005, 24(2):131-135.
114. Jarboe E.A., Miron A., Carlson J.W., et al. Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance. Int J Gynecol Pathol 2009, 28(4):308-315.
115. Wong K.K., Lu K.H., Malpica A., et al. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol 2007, 26(4):404-409.
116. Halperin R., Zehavi S., Hadas E., et al. Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma. Int J Gynecol Pathol 2001, 20(4):341-345.
117. Euscher E.D., Malpica A., Deavers M.T., et al. Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps. Am J Surg Pathol 2005, 29(8):1074-1078.
118. Ambros R.A., Ballouk F., Malfetano J.H., et al. Significance of papillary (villoglandular) differentiation in endometrioid carcinoma of the uterus. Am J Surg Pathol 1994, 18:569-575.
119. Ambros R.A., Malfetano J.H. Villoglandular adenocarcinoma of the endometrium. Am J Surg Pathol 2000, 24(1):155-156.
120. Alkushi A., Irving J., Hsu F., et al. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch 2003, 442(3):271-277.
121. Kamoi S., AlJuboury M.I., Akin M.R., et al. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint. Int J Gynecol Pathol 2002, 21(3):217-223.
122. McCluggage W.G., Sumathi V.P., McBride H.A., et al. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 2002, 21(1):11-15.
123. McCluggage W.G. Immunohistochemistry as a diagnostic aid in cervical pathology. Pathology 2007, 39(1):97-111.
124. McCluggage W.G., Jenkins D. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol 2003, 22(3):231-235.
125. Garg K., Leitao M.M., Wynveen C.A., et al. p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod Pathol 2010, 23(1):80-92.
126. Kumar A., Schneider V. Metastases to the uterus from extrapelvic primary tumors. Int J Gynecol Pathol 1983, 2(2):134-140.
127. Zannoni G.F., Vellone V.G., Fadda G., et al. Colonic carcinoma metastatic to the endometrium: the importance of clinical history in averting misdiagnosis as a primary endometrial carcinoma. Int J Surg Pathol 2009, [Epub ahead of print].
128. Park K.J., Bramlage M.P., Ellenson L.H., et al. Immunoprofile of adenocarcinomas of the endometrium, endocervix, and ovary with mucinous differentiation. Appl Immunohistochem Mol Morphol 2009, 17(1):8-11.
129. Wani Y., Notohara K., Saegusa M., et al. Aberrant Cdx2 expression in endometrial lesions with squamous differentiation: important role of Cdx2 in squamous morula formation. Hum Pathol 2008, 39(7):1072-1079.
130. Houghton O., Connolly L.E., McCluggage W.G. Morules in endometrioid proliferations of the uterus and ovary consistently express the intestinal transcription factor CDX2. Histopathology 2008, 53(2):156-165.
131. Nofech-Mozes S., Ghorab Z., Ismiil N., et al. Endometrial endometrioid adenocarcinoma: a pathologic analysis of 827 consecutive cases. Am J Clin Pathol 2008, 129(1):110-114.
132. Hamilton C.A., Cheung M.K., Osann K., et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006, 94(5):642-646.
133. Rasool N., Fader A.N., Seamon L., et al. Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence. Gynecol Oncol 2010, 116(1):10-14.
134. van Wijk F.H., van der Burg M.E., Burger C.W., et al. Management of recurrent endometrioid endometrial carcinoma: an overview. Int J Gynecol Cancer 2009, 19(3):314-320.
135. Soslow R.A., Slomovitz B.M., Saqi A., et al. Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Mullerian serous carcinomas: clinical divergence without immunophenotypic differences. Gynecol Oncol 2000, 79(3):430-437.
136. Sherman M.E., Sturgeon S., Brinton L.A., et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol 1997, 10:963-968.
137. Dotto J., Tavassoli F.A. Serous intraepithelial carcinoma arising in an endometrial polyp: a proposal for modification of terminology. Int J Surg Pathol 2008, 16(1):8-10.
138. Carcangiu M.L. Uterine pathology in tamoxifen-treated patients with breast cancer. Anat Pathol 1997, 2:53-70.
139. Pothuri B., Ramondetta L., Eifel P., et al. Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers. Gynecol Oncol 2006, 103(3):948-951.
140. Pothuri B., Ramondetta L., Martino M., et al. Development of endometrial cancer after radiation treatment for cervical carcinoma. Obstet Gynecol 2003, 101(5 PT 1):941-945.
141. Lavie O., Barnett-Griness O., Narod S.A., et al. The risk of developing uterine sarcoma after tamoxifen use. Int J Gynecol Cancer 2008, 18(2):352-356.
142. Lavie O., Ben-Arie A., Pilip A., et al. BRCA2 germline mutation in a woman with uterine serous papillary carcinoma-case report. Gynecol Oncol 2005, 99(2):486-488.
143. Gu M., Shi W.J., Barakat R.R., et al. Pap smears in women with endometrial carcinoma. Acta Cytol 2001, 45(4):555-560.
144. Park J.Y., Kim H.S., Hong S.R., et al. Cytologic findings of cervicovaginal smears in women with uterine papillary serous carcinoma. J Korean Med Sci 2005, 20(1):93-97.
145. Tseng P.C., Sprance H.E., Carcangiu M.L., et al. CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma. Obstet Gynecol 1989, 74(3 Pt 1):384-387.
146. Sachmechi I., Kalra J., Molho L., et al. Paraneoplastic hypercalcemia associated with uterine papillary serous carcinoma. Gynecol Oncol 1995, 58:378-382.
147. Ng J.S., Han A.C., Edelson M.I., et al. Uterine papillary serous carcinoma presenting as distant lymph node metastasis. Gynecol Oncol 2001, 80(3):417-420.
148. Cirisano F.D., Robboy S.J., Dodge R.K., et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 1999, 74(3):385-394.
149. Chambers J.T., Merino M., Kohorn E.I., et al. Uterine papillary serous carcinoma. Obstet Gynecol 1987, 69:109-113.
150. Gitsch G., Friedlander M.L., Wain G.V., et al. Uterine papillary serous carcinoma: a clinical study. Cancer 1995, 75:2239-2243.
151. Rosenberg P., Boeryd B., Simonsen E. A new aggressive treatment approach to high-grade endometrial cancer of possible benefit to patients with stage I uterine papillary cancer. Gynecol Oncol 1993, 48:32-37.
152. Lim P., Al Kushi A., Gilks B., et al. Early stage uterine papillary serous carcinoma of the endometrium. Effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome. Cancer 2001, 91(4):752-757.
153. Abeler V.M., Kjorstad K.E. Serous papillary carcinoma of the endometrium: a histopathological study of 22 cases. Gynecol Oncol 1990, 39:266-271.
154. Aquino-Parsons C., Lim P., Wong F., et al. Papillary serous and clear cell carcinoma limited to endometrial curettings in FIGO stage 1a and 1b endometrial adenocarcinoma: treatment implications. Gynecol Oncol 1998, 71:83-86.
155. Bancher-Todesca D., Neunteufel W., Williams K.E., et al. Influence of postoperative treatment on survival in patients with uterine papillary serous carcinoma. Gynecol Oncol 1998, 71:344-347.
156. Gallion H.H., von Nagel J.R., Powell D., et al. Stage I serous papillary carcinoma of the endometrium. Cancer 1989, 63:2224-2228.
157. Verloop J., van Leeuwen F.E., Helmerhorst T.J., et al. Cancer risk in DES daughters. Cancer Causes Control 2010, 21(7):999-1007.
158. Hiller N., Sonnenblick M., Hershko C. Paraneoplastic hypercalcemia in endometrial carcinoma. Oncology 1989, 46(1):45-48.
159. Savvari P., Peitsidis P., Alevizaki M., et al. Paraneoplastic humorally mediated hypercalcemia induced by parathyroid hormone-related protein in gynecologic malignancies: a systematic review. Onkologie 2009, 32(8-9):517-523.
160. Lee L., Garrett L., Lee H., et al. Association of clear cell carcinoma of the endometrium with a high rate of venous thromboembolism. J Reprod Med 2009, 54(3):133-138.
161. Carcangiu M.L., Chambers J.T. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int J Gynecol Pathol 1995, 14:30-38.
162. Tavassoli F.A., Devilee P., International Agency for Research on C, World Health O Pathology and genetics of tumours of the breast and female genital organs 2003, International Agency for Research on Cancer, Lyon (France).
163. Silva E.G., Deavers M.T., Bodurka D.C., et al. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?. Int J Gynecol Pathol 2006, 25(1):52-58.
164. Tafe L., Garg K., Tornos C., et al. Undifferentiated carcinoma of the endometrium and ovary: a clinicopathologic correlation. Mod Pathol 2009, 22(1):238A.